BDRX News & Events

Biodexa Pharmaceuticals announced the closing of an exclusive license with Otsuka Pharmaceutical for OPB-171775. a novel molecular glue intended to be developed for the treatment of gastrointestinal stromal tumours, GIST. The compound also has the potential to be useful in additional indications. In Biodexa's pipeline, OPB-171775 is to be coded MTX240.

Biodexa Pharmaceuticals announced the promotion of Fiona Sharp to CFO and Company Secretary along with her election to the Board of Directors of the Company with immediate effect. Sharp is a senior finance professional having joined the Company as Group Financial Controller in December 2019. During her tenure, she has consistently broadened her remit to include many of the responsibilities of a CFO. Stephen Stamp will relinquish his roles as CFO and Company Secretary but remain as CEO.

Biodexa Pharmaceuticals announced the pricing of a best efforts public offering of an aggregate of 157,000 units, with each unit consisting of one American depositary share, and two Series L warrants, each to purchase one ADS , and 2,891,781 pre-funded units, with each Pre-Funded Unit consisting of one pre-funded warrant to purchase one ADS and two Series L Warrants. The combined public offering price of each ADS Unit is $3.28, and the combined public offering price of each Pre-Funded Unit is $3.2799. The securities comprising the Units are immediately separable and will be issued separately. Each Series L Warrant will expire on the five-year anniversary of the date of issuance and will be immediately exercisable upon issuance at an exercise price of $3.28 per ADS. The aggregate gross proceeds to the Company, before deducting placement agent fees and other offering expenses, are expected to be approximately $10M. The Company intends to use the net proceeds from this offering to fund its development programs, for working capital and for other general corporate purposes. The offering is expected to close on December 19, 2025, subject to the satisfaction of customary closing conditions. Maxim Group is acting as the sole placement agent in connection with the offering.